Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts
Details
Publication Year 2022-10-14,Volume 28,Issue #20,Page 4385-4391
Journal Title
Clinical Cancer Research
Publication Type
Research article
Abstract
PURPOSE: The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and fixed duration (FD cohort). We report tumor debulking and tumor lysis syndrome (TLS) risk category reduction with three cycles of single-agent ibrutinib lead-in before initiation of venetoclax using pooled data from the MRD and FD cohorts. PATIENTS AND METHODS: In both cohorts, patients initially received three cycles of ibrutinib 420 mg/day then 12 cycles of ibrutinib plus venetoclax (5-week ramp-up to 400 mg/day). RESULTS: In the total population (N = 323), the following decreases from baseline to after ibrutinib lead-in were observed: percentage of patients with a lymph node diameter >/=5 cm decreased from 31% to 4%, with absolute lymphocyte count >/=25 x 109/L from 76% to 65%, with high tumor burden category for TLS risk from 23% to 2%, and with an indication for hospitalization (high TLS risk, or medium TLS risk and creatinine clearance <80 mL/minute) from 43% to 18%. Laboratory TLS per Howard criteria occurred in one patient; no clinical TLS was observed. CONCLUSIONS: Three cycles of ibrutinib lead-in before venetoclax initiation provides effective tumor debulking, decreases the TLS risk category and reduces the need for hospitalization for intensive monitoring for TLS.
Keywords
Adenine/analogs & derivatives; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use; Creatinine/therapeutic use; Cytoreduction Surgical Procedures; Humans; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/pathology; Neoplasm, Residual/drug therapy; Piperidines; Sulfonamides; *Tumor Lysis Syndrome/drug therapy/etiology
Department(s)
Clinical Haematology
PubMed ID
35939599
Open Access at Publisher's Site
https://doi.org/10.1158/1078-0432.Ccr-22-0504
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-26 05:45:32
Last Modified: 2024-09-26 05:48:04

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙